Roche Holding AG ’s Actemra did not improve symptoms in patients with early stage Covid 19 pneumonia , scientists conducting a study of the drug in Italy have said . 
The revelation raises questions about the potential of the Swiss drugmakers ’ rheumatoid arthritis drug to treat the infection . 
The study compared patients who received anti inflammation drug Actemra to those given standard treatment , and concluded that Actemra did not reduce severe respiratory symptoms , intensive care visits , or death . 
According to Reuters , the trial ended early after enrolling 126 patients , about one third of the expected number , according to a press release issued by the groups that conducted the study . 
